IMMU-132 and TROP2 Expression: A Review of Key Studies

This article provides an overview of key research articles exploring the effect of IMMU-132 (Sacituzumab Govitecan) on TROP2 expression, a critical target in various cancers. IMMU-132 is an antibody-drug conjugate (ADC) designed to specifically target TROP2-expressing cancer cells.

Key Studies on IMMU-132 and TROP2 Expression:

1. 'Sacituzumab Govitecan, a Novel Antibody-Drug Conjugate, in Patients with Metastatic Triple-Negative Breast Cancer: A Phase I/II Study' by Bardia A, Mayer IA, Vahdat LT, et al. This article presents the results of a phase I/II study evaluating IMMU-132's efficacy and safety in patients with metastatic triple-negative breast cancer. The study investigates the impact of IMMU-132 on TROP2 expression.

2. 'Sacituzumab Govitecan in Refractory Metastatic Triple-Negative Breast Cancer' by Bardia A, Tolaney SM, Loirat D, et al. This article reports the findings of a phase II study examining the efficacy of IMMU-132 in patients with refractory metastatic triple-negative breast cancer. The study explores the relationship between IMMU-132 treatment and TROP2 expression.

3. 'Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers' by Starodub AN, Ocean AJ, Shah MA, et al. This article provides a comprehensive overview of preclinical and clinical data on IMMU-132, including its mechanism of action and impact on TROP2 expression in various cancers.

4. 'Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers' by Ocean AJ, Starodub AN, Bardia A, et al. This article presents the results of a phase I/II study evaluating IMMU-132's efficacy and safety in patients with advanced solid tumors, including pancreatic and gastric cancers. It discusses the effect of IMMU-132 on TROP2 expression in these cancers.

Further Research:

These articles are just a few examples of the extensive research conducted on IMMU-132 and TROP2 expression. To access a comprehensive collection of relevant studies, it is recommended to consult scientific databases like PubMed or Google Scholar.